2022-502424-43-00CompletedPhase 1
A study in healthy men to test how different doses of BI 3000202 are tolerated and how food influences the amount of BI 3000202 in the blood
Boehringer Ingelheim International GmbH1 site in 1 country68 target enrollmentStarted: June 14, 2023Last updated:
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 68
- Locations
- 1
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Sex
- Male
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
CT Disclosure & Data Transparency
Scientific
Boehringer Ingelheim International GmbH
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 1
A study in healthy men to find out how different doses of BI 3009947 are tolerated and how different formulations or food influence how BI 3009947 is taken up into the blood2025-521095-66-00Boehringer Ingelheim International GmbH68
Recruiting
Phase 1
A study in healthy men to test how well different doses of BI 3776528 are tolerated2024-515222-92-00Boehringer Ingelheim International GmbH118
Completed
Phase 1
A study in healthy men to test how well different doses of BI 3731579 are tolerated2023-510318-25-00Boehringer Ingelheim International GmbH64
Completed
Phase 1
A study to evaluate the effect of multiple doses of carbamazepine on how long aticaprant (JNJ-67953964) stays in the body (pharmacokinetics) in healthy adults2022-502951-77-00Janssen - Cilag International20
Completed
Phase 1
A study in healthy men to test how different doses of BI 3031185 are tolerated and how food influences the amount of BI 3031185 in the blood2023-507941-28-00Boehringer Ingelheim International GmbH76